Quarterly ResultAug 12, 2026, 07:08 AM
Kamada Reports Record H1 & Q2 2026 Results; Affirms Guidance
AI Summary
Kamada Ltd. announced record-high financial results for the first half and second quarter of 2026, demonstrating double-digit profitable growth. The company reported H1 revenues of $100.2 million and Q2 revenues of $54.9 million, while also affirming its 2026 annual guidance. Additionally, Kamada secured a significant three-year, $50 million plasma supply agreement and announced that its CFO, Chaime Orlev, will transition out of his role by year-end.
Key Highlights
- Reported record-high First Half 2026 Revenues of $100.2 Million, a 13% increase year-over-year.
- Achieved record-high Second Quarter 2026 Revenues of $54.9 Million, up 23% year-over-year.
- Affirmed 2026 annual guidance of $200 Million - $205 Million in revenues and $50 Million - $53 Million of Adjusted EBITDA.
- Secured a three-year sales agreement of approximately $50 Million to supply plasma to a leading biopharmaceutical company.
- First Half 2026 Adjusted EBITDA was $25.7 Million, a 14% increase year-over-year.
- Second Quarter 2026 Adjusted EBITDA was $14.1 Million, up 29% year-over-year.
- Net income for the First Half 2026 was $13.4 Million, up 18% year-over-year.
- CFO Chaime Orlev will transition out of his role effective December 31, 2026, with a search for a successor underway.
Price Impact
More from KMDA